c-Met receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
During the summer of 1936, experiments were carried out at RAF Biggin Hill to examine what effect the presence of radar would have on an air battle. Assuming RDF would provide them 15 minutes' warning, they developed interception techniques putting fighters in front of the bombers with increasing efficiency. They found the main problems were finding their own aircraft's location, and ensuring the fighters were at the right altitude. In a similar test against the operational radar at Bawdsey in 1937, the results were comical. As Dowding watched the ground controllers scramble to direct their fighters, he could hear the bombers passing overhead. He identified the problem not as a technological one, but in the reporting. The pilots were being sent too many reports, often contradictory. This realization led to the development of the Dowding system, an extensive network of telephone lines reporting to a central "filter room" in London where the reports from the radar stations were collected and collated, and fed back to the pilots in a clear format. The system as a whole was enormously manpower intensive. By the outbreak of war in September 1939, there were 21 operational Chain Home stations. After the Battle of France in 1940 the network was expanded to cover the west coast and Northern Ireland. The Chain continued to be expanded throughout the war, and by 1940 it stretched from Orkney in the north to Weymouth in the south. This provided radar coverage for the entire Europe-facing side of the British Isles, able to detect high-flying targets well over France.
Germany is the seventh-largest country in Europe. It borders Denmark to the north; Poland and the Czech Republic to the east; Austria and Switzerland to the south; and France, Luxembourg, Belgium, and the Netherlands to the west. Germany is also bordered by the North Sea (Nordsee) in the northwest and the Baltic Sea (Ostsee) in the northeast. German territory covers 357,022 km2 (137,847 sq mi). Elevation ranges from the mountains of the Alps (with the highest point being the Zugspitze at 2,963 metres or 9,721 feet) in the south to the shores of the North Sea and the Baltic Sea. The forested uplands of central Germany and the lowlands of northern Germany (lowest point: in the municipality Neuendorf-Sachsenbande, Wilstermarsch, at 3.54 metres or 11.6 feet below sea level) are traversed by major rivers such as the Rhine, Danube, and Elbe. Significant natural resources include iron ore, coal, potash, timber, lignite, uranium, copper, natural gas, salt, and nickel.
==== Assays ==== Immunoprecipitation, immunoblotting and enzyme-link immunosorbent assay (ELISA) Poot et al. 2013 determined that immunoprecipitation for antibodies against envoplakin and periplakin or alpha2-macroglobulin-like–1 is the most sensitive test. However, alpha2-macroglobulin-like-1 can also be detected in patients with toxic epidermal necrosis.
Sources: en.wikipedia.org
== Education and career == Flegg received her PhD in Applied Mathematics from Queensland University of Technology in 2009. Her dissertation, "Mathematical Modelling of Chronic Wound Healing", was supervised by Dr. Sean McElwain. From 2010 to 2013, she was a researcher at the University of Oxford developing mathematical models for the spread of resistance to antimalarial drugs. From 2014 to early 2017, she was a mathematical lecturer in the School of Mathematical Sciences at Monash University. In May 2017, she joined the School of Mathematics and Statistics at the University of Melbourne as a senior lecturer in Applied Mathematics and was promoted to associate professor in 2020 and again to Professor in 2022. Flegg is an expert in the field of mathematical biology, with special focus in infectious disease epidemiology, wound healing and tumor growth. As of 2020, Flegg also serves as an editorial board member for PLOS Computational Biology, eLife and the Bulletin of Mathematical Biology.
== Sources == B vitamins are found in abundance in meat, eggs, and dairy products. Processed carbohydrates such as sugar and white flour tend to have lower B vitamin content than their unprocessed counterparts. For this reason, it is common in many countries (including the United States) that the B vitamins thiamine, riboflavin, niacin, and folic acid are added back to white flour after processing. This is referred to as "enriched flour" on food labels. B vitamins are particularly concentrated in meat such as turkey, tuna and liver. Sources for B vitamins also include spinach, legumes (pulses or beans), whole grains, asparagus, potatoes, bananas, chili peppers, breakfast cereals. The B12 vitamin is not abundantly available from plant products (although it has been found in moderate abundance in fermented vegetable products, certain seaweeds, and in certain mushrooms, with the bioavailability of the vitamin in these cases remaining uncertain), making B12 deficiency a legitimate concern for those maintaining a vegan diet. Manufacturers of plant-based foods will sometimes report B12 content, leading to confusion about what sources yield B12. The confusion arises because the standard US Pharmacopeia (USP) method for measuring the B12 content does not measure the B12 directly. Instead, it measures a bacterial response to the food. Chemical variants of the B12 vitamin found in plant sources are active for bacteria, but cannot be used by the human body. This same phenomenon can cause significant over-reporting of B12 content in other types of foods as well.
Peripheral membrane proteins may interact with other proteins or directly with the lipid bilayer. In the latter case, they are then known as amphitropic proteins. Some proteins, such as G-proteins and certain protein kinases, interact with transmembrane proteins and the lipid bilayer simultaneously. Some polypeptide hormones, antimicrobial peptides, and neurotoxins accumulate at the membrane surface prior to locating and interacting with their cell surface receptor targets, which may themselves be peripheral membrane proteins. The phospholipid bilayer that forms the cell surface membrane consists of a hydrophobic inner core region sandwiched between two regions of hydrophilicity, one at the inner surface and one at the outer surface of the cell membrane (see lipid bilayer article for a more detailed structural description of the cell membrane). The inner and outer surfaces, or interfacial regions, of model phospholipid bilayers have been shown to have a thickness of around 8 to 10 Å, although this may be wider in biological membranes that include large amounts of gangliosides or lipopolysaccharides. The hydrophobic inner core region of typical biological membranes may have a thickness of around 27 to 32 Å, as estimated by Small angle X-ray scattering (SAXS). The boundary region between the hydrophobic inner core and the hydrophilic interfacial regions is very narrow, at around 3 Å, (see lipid bilayer article for a description of its component chemical groups).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.